High initial drug doses may reduce cancer drug resistance

Download PDF Copy

Reviewed

Aging-USAug 6 2024

On July 28, 2024, Mikhail V. Blagosklonny M.D., Ph.D., from Roswell Park Comprehensive Cancer Center published a new editorial in Volume 16, Issue 14 of Aging (listed by MEDLINE/PubMed as "Aging (Albany NY)" and "Aging-US" by Web of Science), entitled, "Targeted cancer therapy: the initial high concentration may slow down the selection for resistance."

"Unfortunately, any targeted therapy is, always, started with low levels of the drug in the organism, selecting for drug resistance. One should propose that initial drug levels must be maximized, and durations may be minimized, ideally, as portions of preemptive combination of targeted drugs."

Source:

Aging-US

Journal reference:

Blagosklonny, M. V. (2024). Targeted cancer therapy: the initial high concentration may slow down the selection for resistance. Aging. doi.org/10.18632/aging.206046.

Posted in: Medical Research News | Medical Condition News

Comments (0)

Download PDF Copy

Suggested Reading

New tool helps identify risky medications for older cancer patients

Study validates deep learning model for predicting future lung cancer risk in Black population

Lung tumors rewire immune cells in the bone marrow before they reach cancer sites

Cancer cells found to use ketones as alternate fuel for growth

New tool can predict where deadly brain cancer might reappear

IFITM3 found to be critical regulator of immunotherapy sensitivity in small cell lung cancer

NYU Langone strengthens world-leading GI cancer program with renowned leaders

City of Hope launches innovative national clinical trials model to expand access to cancer treatments

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.

Post a new comment

(Logout)

Post

Sign in to keep reading

We're committed to providing free access to quality science. By registering and providing insight into your preferences you're joining a community of over 1m science interested individuals and help us to provide you with insightful content whilst keeping our service free.